Compare Expedia Group Inc (EXPE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs ResMed Inc. — how do they compare? Expedia Group Inc trades at $326 (market cap $38.53B), while ResMed Inc. trades at $225.19 (market cap $32.61B). The key difference: Expedia Group Inc is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| EXPE | RMD | |
|---|---|---|
Market Cap | $38.53B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $321.07 | $293.73 |
52-Week Low | $188.51 | $182.82 |
Enterprise Value | $37.09B | $31.97B |
Dividend Yield | 0.6% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $328.08, up 4.48% on the day, reflecting strong momentum after Q2 2026 earnings beat. The stock shows a bullish technical trend with moving averages aligned positively, while fundamentals highlight robust revenue growth, expanding margins, and consistent earnings outperformance. Recent news emphasizes AI integration and B2B growth driving upward guidance revisions.
Outlook remains favorable with raised full-year revenue guidance and solid cash flow generation, though elevated valuation multiples and overbought RSI levels near-term pose risks. Analyst consensus leans neutral with a $322.95 price target slightly below current levels, suggesting cautious optimism amid execution and competitive pressures.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
